Treatment with a D2R agonist has been shown to block tumor growth, induce the regression of an aberrant blood supply, and normalize blood vessels in a mutant mouse model, and chronic treatment is able to restore the disturbed balance between proangiogenic and antiangiogenic factors [194]. Here, DRD2 is linked to neoplasm.